Pharmacogenetics and pharmacoepigenetics of gemcitabine

被引：24

作者：

Candelaria, M. ^{[3
]}

de la Cruz-Hernandez, E. ^{[2
]}

Perez-Cardenas, E. ^{[2
]}

Trejo-Becerril, C. ^{[2
]}

Gutierrez-Hernandez, O. ^{[2
]}

Duenas-Gonzalez, A. ^{[1
]}

机构：

[1] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Cancerol, Unit Biomed Res Canc, Mexico City 04510, DF, Mexico

[2] Inst Nacl Cancerol INCan, Basic Res Div, Mexico City, DF, Mexico

[3] Inst Nacl Cancerol INCan, Div Clin Res, Mexico City, DF, Mexico

来源：

MEDICAL ONCOLOGY | 2010年 / 27卷 / 04期

关键词：

Gemcitabine; Pharmacogenetics; Pharmacoepigenetics; Epigenetics; Antimetabolites; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1; DEOXYCYTIDINE KINASE PROMOTER; MESSENGER-RNA EXPRESSION; REDUCED FOLATE CARRIER; RIBONUCLEOTIDE REDUCTASE; FUNCTIONAL-CHARACTERIZATION; DNA METHYLATION; MEMBRANE TRANSPORTERS; PRETREATED PATIENTS; CYTIDINE-DEAMINASE;

D O I：

10.1007/s12032-009-9349-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gemcitabine (2',2'-difluoro 2'deoxycytidine, dFdC) is an analog of cytosine with distinctive pharmacological properties and a wide antitumor-activity spectrum. The pharmacological characteristics of gemcitabine are unique because two main classes of genes are essential for its antitumor effects: membrane transporter protein-coding genes, whose products are responsible for drug intracellular uptake, as well as enzyme-coding genes, which catalyze its activation and inactivation. The study of the pharmacogenetics and pharmacoepigenetics of these two gene classes is greatly required to optimize the drug's therapeutic use in cancer. This review aims to provide an update of genetic and epigenetic bases that may account for interindividual variation in therapeutic outcome exhibited by gemcitabine.

引用

页码：1133 / 1143

页数：11

共 99 条

[41] Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations [J].

Gray, JH ;

Mangravite, LM ;

Owen, RP ;

Urban, TJ ;

Chan, W ;

Carlson, EJ ;

Huang, CC ;

Kawamoto, M ;

Johns, SJ ;

Stryke, D ;

Ferrin, TE ;

Giacomini, KM .

MOLECULAR PHARMACOLOGY, 2004, 65 (03) :512-519

[42] Molecular Cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta [J].

Griffiths, M ;

Yao, SYM ;

Abidi, F ;

Phillips, SEV ;

Cass, CE ;

Young, JD ;

Baldwin, SA .

BIOCHEMICAL JOURNAL, 1997, 328 :739-743

[43]

HEINEMANN V, 1992, CANCER RES, V52, P533

[44]

HEINEMANN V, 1990, MOL PHARMACOL, V38, P567

[45] Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B [J].

Hopper-Borge, Elizabeth ;

Xu, Xiu ;

Shen, Tong ;

Shi, Zhi ;

Chen, Zhe-Sheng ;

Kruh, Gary D. .

CANCER RESEARCH, 2009, 69 (01) :178-184

[46]

HUANG P, 1991, CANCER RES, V51, P6110

[47] Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy [J].

Huang, Ying .

CANCER AND METASTASIS REVIEWS, 2007, 26 (01) :183-201

[48] Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells [J].

Jordheim, LP ;

Guittet, O ;

Lepoivre, M ;

Galmarini, CM ;

Dumontet, C .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (08) :1268-1276

[49]

Kalykaki A, 2008, ANTICANCER RES, V28, P495

[50] Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma [J].

Kastrup, Ingelise Bjerring ;

Worm, Jesper ;

Ralfkiaer, Elisabeth ;

Hokland, Peter ;

Guldberg, Per ;

Gronbaek, Kirsten .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (01) :61-66

← 1 2 3 4 5 6 7 8 9 10 →